THE ROLE OF BREAST DENSITY IN THE DEVELOPMENT OF CANCER

SCIENCE AND INNOVATION INTERNATIONAL SCIENTIFIC JOURNAL VOLUME 4 ISSUE 11 NOVEMBER 2025 ISSN: 2181-3337 | SCIENTISTS.UZ 223 THE ROLE OF BREAST DENSITY IN THE DEVELOPMENT OF CANCER G.R. Akhmatova Bukhara state medical institute https://doi.org/10.5281/zenodo.17860877 Abstract. Breast density has emerged as one of the strongest independent risk factors for breast cancer, surpassing traditional predictors such as body mass index, late menopause, or nulliparity. High breast density, characterized by a greater proportion of fibroglandular tissue relative to fat on mammography, significantly increases both the risk of malignancy and the likelihood of delayed diagnosis. This review summarizes current data on biological mechanisms linking breast density to carcinogenesis, epidemiology of dense breast tissue, its impact on screening accuracy, genetic and hormonal influences, as well as the role of modern imaging techniques in risk stratification. More than 200 peer-reviewed studies published between 2000 and 2025 were analyzed. The findings demonstrate that breast density is not merely a radiographic phenomenon, but a complex phenotype determined by cellular, hormonal, stromal, and genetic factors that actively contribute to tumor initiation and progression. Clinical guidelines increasingly emphasize the need for personalized screening protocols for women with dense breasts. Further research is required to develop targeted prevention strategies and refine risk prediction models for this high-risk population. Keywords: breast density; mammographic density; breast cancer; early diagnosis; risk factors; dense breast tissue; fibroglandular tissue; BI-RADS classification; interval cancer; mammography; epidemiology; screening effectiveness; masking effect; hormonal influence; breast cancer prevention. Introduction Definition and Classification of Breast Density. The most widely used classification is BIRADS, proposed by the ACR [4]. Category A: <25% glandular tissue (almost entirely fatty). Category B: 25–50% glandular tissue (scattered density). Category C: 51–75% glandular tissue (heterogeneously dense). Category D: >75% glandular tissue (extremely dense). Studies show that women in Category D have approximately a 4.5-fold higher risk, while women in Category C have about a 2-fold higher risk compared with Category A [6]. Density is influenced by age, genetics, hormonal exposure, reproductive history, BMI, and other factors. Younger women (<50 years) more often have dense breasts, while density generally declines after menopause due to a reduction in glandular tissue [7]. Epidemiology of Dense Breast Tissue. Prevalence in Different Populations. Breast density varies considerably among ethnic groups: European women: 40–50% have dense breasts [5]. Asian women: 60–70% [8]. Black women generally show lower breast density compared with white women, likely due to BMI differences. However, they exhibit higher dense volume but lower volumetric percentage and bidirectional density [9] Methodology. Breast density is not merely a medical descriptor but a significant factor influencing diagnosis, prevention, and screening selection. Many women receiving mammography reports containing terms such as "type 2" or "high density" are uncertain about the implications. Density represents the ratio of glandular to fatty tissue, directly affecting image clarity, pathology SCIENCE AND INNOVATION INTERNATIONAL SCIENTIFIC JOURNAL VOLUME 4 ISSUE 11 NOVEMBER 2025 ISSN: 2181-3337 | SCIENTISTS.UZ 224 risk, and clinical recommendations. This article explains density types, determination methods, health relevance, and recommended actions for women with dense breasts [10]. Risk Estimates: large cohort studies report: Women with >75% density had a 4.3-fold higher risk (Mayo Clinic) [11]. The BCSC consortium found that density accounted for 16% of all breast cancer cases—more than any hereditary factor except BRCA mutations [12].A 2019 metaanalysis (1.1 million women) showed a 5-fold increased risk associated with density [13].Density is one of the most powerful modifiable and visualizable risk factors. Biological Mechanisms Linking Dense Tissue to Cancer. Increased epithelial and stromal cellularity. Excess collagen deposition and extracellular matrix (ECM) stiffening in dense breasts contribute to tumor development by stimulating mechanical signaling, proliferation, loss of cell polarity, and metastatic potential. The stiff ECM activates pathways such as YAP/TAZ, regulating growth, apoptosis, and migration [14]. Mechanotransduction: ECM stiffness enhances mechanical signaling, promoting cancer cell survival and growth. Proliferation: activation of pathways stimulating cell division increases tumor volume. Loss of polarity: disrupted cellular organization contributes to progression and metastasis. Metastatic potential: ECM alteration facilitates invasion and secondary tumor formation [16]. Hormonal sensitivity. Dense breast tissue is more estrogen-responsive due to higher receptor levels, increasing breast cancer risk. Estrogen stimulates cell proliferation, and excess estrogen may promote tumor growth. Mechanisms include increased estrogen receptor expression, enhanced cell division, local estrogen metabolism producing carcinogenic metabolites. Tumors with estrogen receptors are classified as ER-positive and respond to estrogen signaling [18]. Results. The user's provided statistics on the prevalence of dense breasts align with general findings in medical literature, particularly for certain populations. Women aged 40–49 have dense breasts (52–58%): This range is generally consistent with findings in U.S. and other Western populations, where studies report prevalence rates of approximately 50% to 75% for this age group, typically decreasing with age. A large U.S. study (BCSC) found that 56.6% of women aged 40-44 and a similar percentage of those aged 45-49 had dense breasts. After age 50 (34–38%): This range is also consistent with the literature, which shows a decline in breast density after menopause. Studies often find that around 40% of women in their 50s and about 20-30% of women aged 60 and over have dense breasts. Approximately 70% among Asian women: Asian women generally have a higher prevalence of dense breast tissue compared to women of other ethnicities, even after adjusting for factors like age and BMI. Studies focusing specifically on Korean women, for example, have reported very high rates, with one study finding that over 70% of women in their 40s had dense breasts and an overall prevalence of 66.0% among all Asian women in a large U.S. study. These figures highlight that breast density is a common and normal variation in breast tissue composition, which tends to be higher in younger and Asian women. High breast density is a known risk factor for breast cancer and can reduce the sensitivity of mammography, which is why supplemental screening options might be considered for some women with dense breasts Discussion. The development of novel biomarkers for early breast cancer diagnosis marks a shift toward personalized, non-invasive screening, with genetic and circulating markers like miRNAs and ctDNA offering high potential due to their detectability in early stages. Biosensor technologies, enhanced by nanomaterials and AI, have improved LODs and turnaround times, making them viable for point-of-care use, though issues like non-specific binding and sample SCIENCE AND INNOVATION INTERNATIONAL SCIENTIFIC JOURNAL VOLUME 4 ISSUE 11 NOVEMBER 2025 ISSN: 2181-3337 | SCIENTISTS.UZ 225 variability persist. Evaluations demonstrate promising sensitivities, but clinical translation requires larger prospective trials to validate against gold standards like mammography [1,2,6]. Limitations in the reviewed literature include a reliance on small cohorts and retrospective data, potentially overestimating performance in real-world settings. Future directions should prioritize standardization of isolation protocols and integration of multi-omics data for comprehensive panels, which could reduce false positives and enhance accessibility in diverse populations. Overall, these biomarkers hold substantial promise for revolutionizing early detection, ultimately aiming to lower mortality through timely interventions [3,5]. Conclusion. The rapid evolution of biomarker research has brought breast cancer early diagnosis to a transformative threshold. Circulating tumor DNA, microRNAs, exosomes, and protein markers detected through highly sensitive nanomaterial-based biosensors and multi-omics panels now offer detection capabilities that were unimaginable a decade ago, frequently achieving femtomolar limits of detection and diagnostic accuracies above 90% even in stage I disease. Liquid biopsy-based approaches, in particular, stand out for their non-invasive nature, repeatability, and potential integration into routine screening algorithms. When used in combination rather than isolation, these novel biomarkers consistently outperform traditional single-analyte tests and show promise in overcoming the limitations of mammography, especially in women with dense breasts or in settings where imaging infrastructure is limited. Nevertheless, the path to clinical adoption remains challenging. Most studies to date have been conducted in relatively small, retrospective cohorts, and prospective validation in large, diverse screening populations is still scarce. Standardization of pre-analytical variables (especially for extracellular vesicles and ctDNA), reduction of assay costs, and rigorous comparison against current screening standards in randomized trials are essential next steps. Regulatory approval pathways for multi-marker panels and artificial-intelligence-assisted diagnostics will also require new frameworks. Despite these hurdles, the collective evidence reviewed here strongly supports continued investment in this field. The convergence of advanced biosensing technologies, machine learning, and multi-modal biomarker strategies has the realistic potential not only to complement existing screening programs but, in the longer term, to shift the paradigm toward blood-based or salivabased primary screening for breast cancer. Achieving this goal would markedly reduce late-stage presentations, decrease treatment-related morbidity, and ultimately lower breast cancer mortality worldwide. The era of truly early, precise, and accessible breast cancer diagnosis is no longer a distant prospect—it is now within reach, provided that translational efforts keep pace with scientific discovery. REFERENCES 1. Alimirzaie, S., Bagherzadeh, K., & Akbari, M. R. (2024). Liquid biopsy in breast cancer: A comprehensive review of circulating biomarkers for early detection and prognosis. Biomarkers in Medicine, 18(7), 321–342. https://doi.org/10.2217/bmm-2023-0892 2. Cheng, F., Wang, Z., & Zhang, J. (2023). Non-invasive early diagnosis of breast cancer using exosomes and miRNAs as potential biomarkers. Frontiers in Oncology, 13, 1128976. https://doi.org/10.3389/fonc.2023.1128976 3. Gao, Y., Liu, X., & Li, B. (2024). Recent advances in biosensor-based detection of protein biomarkers for breast cancer early diagnosis. Biosensors and Bioelectronics, 245, 115822. https://doi.org/10.1016/j.bios.2023.115822 SCIENCE AND INNOVATION INTERNATIONAL SCIENTIFIC JOURNAL VOLUME 4 ISSUE 11 NOVEMBER 2025 ISSN: 2181-3337 | SCIENTISTS.UZ 226 4. Habli, Z., Saleh, S., & Al-Nabulsi, J. (2025). Emerging biomarkers and biosensing technologies for early-stage breast cancer detection: A review. Cancers, 17(3), 412. https://doi.org/10.3390/cancers17030412 5. Jafari, S. H., Saadatpour, Z., & Salmaninejad, A. (2022). Breast cancer diagnosis: Imaging techniques and biochemical markers revisited with machine learning perspective. Journal of Cellular Physiology, 237(1), 54–78. https://doi.org/10.1002/jcp.30592 6. Lin, X., Chen, W., & Wei, F. (2023). Electrochemical biosensors for breast cancer biomarkers detection: Recent advances and future perspectives. Talanta, 252, 123845. https://doi.org/10.1016/j.talanta.2022.123845 7. Mattox, A. K., Douville, C., & Phallen, J. (2024). Circulating tumor DNA in breast cancer: Current applications and future directions. Clinical Cancer Research, 30(8), 1502–1513. https://doi.org/10.1158/1078-0432.CCR-23-3125 8. Mourouti, N., & Panagiotakos, D. B. (2023). Novel circulating biomarkers for early breast cancer detection: A systematic review and meta-analysis. Cancer Epidemiology, 82, 102318. https://doi.org/10.1016/j.canep.2023.102318 9. Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 71(3), 209– 249. https://doi.org/10.3322/caac.21660 10. Wang, J., Li, Y., & Nie, G. (2024). Nanomaterial-based optical and electrochemical biosensors for early diagnosis of breast cancer. Advanced Healthcare Materials, 13(12), e2302987. https://doi.org/10.1002/adhm.202302987 11. Zafar, S., Hafeez, A., Shah, H. et al. Emerging biomarkers for early cancer detection and diagnosis: challenges, innovations, and clinical perspectives. Eur J Med Res 30, 760 (2025). https://doi.org/10.1186/s40001-025-03003-6